Upvote
Downvote
Director, Business Development
Share Job
- Suggest Revision
- The company is powered by its proprietary TPD drug discovery platform, which integrates degrader chemistry design principles and screening libraries with cell-based, target-specific degradation assays, including an ultra-high-throughput screening platform, to enable the identification of drug-like, cell-permeable degrader molecules.
- This integrated TPD drug discovery approach has led to the discovery of novel, selective direct degraders and molecular glue drug candidates, and two unprecedented E3 ligases.
- The pharmacology associated with IKZF2 degradation is orthogonal to checkpoint inhibitor therapy driving immune cell activation.
- Additionally, Plexium is progressing two lead optimization stage degraders drug discovery program, a highly selective director degrader of CRAF and a highly selective molecular glue degrader of CDK2.
- Cultivate and maintain a current perspective on market trends, including pre-clinical and clinical programs in the broader pharma/biotech community along with strategic positioning of pharma drug discovery pipelines
Active Job
Updated TodaySimilar Job
Relevance
Active